165 related articles for article (PubMed ID: 24045927)
1. Impact of cardiovascular comorbidity on ovarian cancer mortality.
Shinn EH; Lenihan DJ; Urbauer DL; Basen-Engquist KM; Valentine A; Palmero L; Woods ML; Patel P; Nick AM; Shahzad MM; Stone RL; Golden A; Atkinson E; Lutgendorf SK; Sood AK
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2102-9. PubMed ID: 24045927
[TBL] [Abstract][Full Text] [Related]
2. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
3. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
4. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.
Hosono S; Kajiyama H; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2011 Oct; 16(5):524-32. PubMed ID: 21431342
[TBL] [Abstract][Full Text] [Related]
5. The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study.
O'Malley CD; Shema SJ; Cress RD; Bauer K; Kahn AR; Schymura MJ; Wike JM; Stewart SL
J Womens Health (Larchmt); 2012 Sep; 21(9):887-94. PubMed ID: 22816528
[TBL] [Abstract][Full Text] [Related]
6. Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
Dilley S; Erickson BK; Phillips CE; Kennemer CR; Zhang B; Matin T; Martin JY; Shah MM; Michael Straughn J; Leath CA
Gynecol Oncol; 2018 Apr; 149(1):49-52. PubMed ID: 29605050
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
8. Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.
Kolomeyevskaya NV; Szender JB; Zirpoli G; Minlikeeva A; Friel G; Cannioto RA; Brightwell RM; Grzankowski KS; Moysich KB
Int J Gynecol Cancer; 2015 Nov; 25(9):1587-92. PubMed ID: 26273932
[TBL] [Abstract][Full Text] [Related]
9. Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
Kumar A; Hurtt CC; Cliby WA; Martin JR; Weaver AL; McGree ME; Langstraat CL; Bakkum-Gamez JN
Gynecol Oncol; 2017 Dec; 147(3):514-520. PubMed ID: 28947173
[TBL] [Abstract][Full Text] [Related]
10. The influence of comorbidity on mortality in ovarian cancer patients.
Stålberg K; Svensson T; Lönn S; Kieler H
Gynecol Oncol; 2014 May; 133(2):298-303. PubMed ID: 24582801
[TBL] [Abstract][Full Text] [Related]
11. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
13. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
14. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
15. Long-term mortality among women with epithelial ovarian cancer.
Dinkelspiel HE; Champer M; Hou J; Tergas A; Burke WM; Huang Y; Neugut AI; Ananth CV; Hershman DL; Wright JD
Gynecol Oncol; 2015 Aug; 138(2):421-8. PubMed ID: 26050923
[TBL] [Abstract][Full Text] [Related]
16. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease.
Bristow RE; Chang J; Ziogas A; Randall LM; Anton-Culver H
Gynecol Oncol; 2014 Feb; 132(2):403-10. PubMed ID: 24361578
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
19. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period.
Zhou Q; Zhu C; Shen Z; Zhang T; Li M; Zhu J; Qin J; Xie Y; Zhang W; Chen R; Wang G; Qian L; Wu D; Nashan B; Zhou Y
Eur J Surg Oncol; 2020 May; 46(5):855-861. PubMed ID: 32001042
[TBL] [Abstract][Full Text] [Related]
20. A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
Garcia C; Yao A; Camacho F; Balkrishnan R; Cantrell LA
Gynecol Oncol; 2017 Aug; 146(2):346-350. PubMed ID: 28499649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
